entity

CNS

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about CNS: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

15Connections

17Hypotheses

8Analyses

0Outgoing

15Incoming

2Experiments

17Debates

No AI portrait yet

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Gut-First vs Brain-First Alpha-Synuclein Propagation in Parkinson's Disease

mechanism · 2399 words

→

Validated Hypothesis: pH-Sensitive Bispecific Antibody Targeting Transferrin Receptor for CNS Delivery

hypothesis · 3792 words

→

Outgoing (0)

Target	Relation	Type	Str
No outgoing edges

Incoming (15)

Source	Relation	Type	Str
cell-types-nodes-ranvier-neurod	describes	wiki	1.00
BI-hTFR1	mediates	protein	0.90
39009412	penetrate	paper	0.90
29563219	is the primary lipid carrier within	paper	0.90
38898538	is expressed outside	paper	0.90
BDNF	expressed_in	protein	0.87
JEV	infects	virus	0.80
MICROGLIA	expressed_in	cell_type	0.76
MS	regulates	disease	0.72
therapeutic agents	associated_with	drug	0.70
ACY-738	associated_with	drug	0.70
peripheral immune system	regulates	process	0.70
Eliglustat	inhibits	drug	0.70
venglustat	associated_with	drug	0.70
DAM	expressed_in	cell_type	0.68

Targeting Hypotheses (17)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
pH-Sensitive Bispecific Antibody Targeting Transferrin Recep	0.800	neurodegeneration	Blood-brain barrier antibody transport m
Focused Ultrasound with Microbubble Contrast Agents for Anti	0.762	neurodegeneration	Blood-brain barrier antibody transport m
LRP1-Mediated Transcytosis for CNS Antibody Delivery	0.680	neurodegeneration	Blood-brain barrier antibody transport m
AQP4 Dysregulation Promotes Neuroinflammation Through Impair	0.680	neurodegeneration	What are the specific molecular mechanis
Leaky Gut LPS Translocation Activates Systemic TLR4/MyD88 Si	0.670	neurodegeneration	How does gut microbiome dysbiosis contri

Glial-Autophagy-Senescence Coupling Defines CNS Therapeutic	0.614	molecular-biology	What is the optimal therapeutic window t
Brain-Ester Prodrug Strategy for CNS-Selective HDAC6 Inhibit	0.570	pharmacology	How can CNS-selective HDAC/DNMT inhibito
MFSD2A-Targeted Lysophosphatidylcholine-SPM Conjugates as CN	0.551	neuropharmacology	What determines blood-brain barrier pene
Pharmacogenomic CNS Drug Optimization Platform	0.524	neurodegeneration	How do neurodegeneration gene expression
CCR2+ Monocyte Depletion as Restoration of CNS Immune Privil	0.501	immunomics	Systemic immune profiling in neurodegene
CNS-Peripheral Cytokine Compartmentalization	0.455	clinical-neurology	Why do systemic anti-inflammatory drugs
C1q-Alectinib Complexation Enhances CNS Penetration via Micr	0.415	molecular-biology	Does Alectinib truly bind C1q directly w
CCL2 Gradient Disruption via Astrocytic CXCL12 Upregulation	0.380	immunomics	Systemic immune profiling in neurodegene
CCR2+ Monocyte Reprogramming via IL-10 Enhancement for CNS I	0.380	immunomics	Systemic immune profiling in neurodegene
CRP-Mediated CCR2+ Monocyte Recruitment Drives Microglial IL	0.380	immunomics	Systemic immune profiling in neurodegene
LDLR-Mediated Reverse Cholesterol Transport Modulation for C	0.380	neuropharmacology	What is the actual quantitative contribu
hs-CRP-Driven CCR2+ Monocyte Recruitment Disrupts CNS Immune	0.357	immunomics	Systemic immune profiling in neurodegene

Mentioning Analyses (8)

Scientific analyses that reference this entity

Systemic immune profiling in neurodegeneration: peripheral inflammation as drive

immunomics | 2026-04-16 | 13 hypotheses Top: 0.565

How do synthetic EVs achieve brain-specific targeting while avoiding reticuloend

drug delivery | 2026-04-15 | 0 hypotheses

What determines blood-brain barrier penetration kinetics for specialized pro-res

neuropharmacology | 2026-04-13 | 2 hypotheses Top: 0.551

What is the therapeutic window between GCS inhibition efficacy and systemic toxi

neurodegeneration | 2026-04-11 | 0 hypotheses

Do tau-specific HSP90 conformational states exist that differ from other client

structural biology | 2026-04-10 | 0 hypotheses

Experiments (2)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Autophagy receptor identification for stress granule elimination	exploratory	neurodegenerative diseases	0.900	0.00	cultured cells under arsenite	proposed	N/A
Epigenetic clocks association with brain aging patterns in older women	exploratory	cognitive impairment and demen	0.900	0.00	human patients	proposed	N/A

Related Papers (5)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disea [PMID:33182554]	Marogianni C, Sokratous M, Dardiotis E,	International journal of molec	2020
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disea [PMID:33182554]	Marogianni C, Sokratous M, Dardiotis E,	International journal of molec	2020
Multiple Sclerosis Pathology. [PMID:29358320]	Lassmann H	Cold Spring Harbor perspective	2018

Debates (17)

Multi-agent debates referencing this entity

Extended debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 6 · Score: 0.95 · 2026-04-27

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 4 · Score: 0.44 · 2026-04-27

Hypothesis debate: SASP Modulation Rather Than Cell Elimination

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Should metabolic reprogramming via SIRT1/NAD+/PGC-1alpha axis be prioritized to

closed · Rounds: 4 · Score: 0.81 · 2026-04-23

The abstract states that AQP4 'is part of the pathogenesis' of CNS disorders and

closed · Rounds: 4 · Score: 0.76 · 2026-04-21

The debate hinged on whether HSP90 adopts unique conformations when bound to tau

closed · Rounds: 4 · Score: 0.30 · 2026-04-21

The debate identified systemic toxicity as a major concern for glucosylceramide

closed · Rounds: 4 · Score: 0.50 · 2026-04-20

How does chronic peripheral inflammation interact with CNS neuroimmune pathways

closed · Rounds: 4 · Score: 0.50 · 2026-04-18

Related Research

Hypotheses and analyses mentioning CNS in their description or question text

Glial-Autophagy-Senescence Coupling Defines CNS Therapeutic Windows

Score: 0.614 · molecular-biology · 2026-04-21

## Mechanistic Overview Glial-Autophagy-Senescence Coupling Defines CNS Therapeutic Windows starts from the claim that m

Brain-Ester Prodrug Strategy for CNS-Selective HDAC6 Inhibition

Score: 0.570 · pharmacology · 2026-04-21

## Mechanistic Overview Brain-Ester Prodrug Strategy for CNS-Selective HDAC6 Inhibition starts from the claim that modul

MFSD2A-Targeted Lysophosphatidylcholine-SPM Conjugates as CNS-Penetrant Pro-Reso

Score: 0.551 · neuropharmacology · 2026-04-13

## Mechanistic Overview MFSD2A-Targeted Lysophosphatidylcholine-SPM Conjugates as CNS-Penetrant Pro-Resolving Prodrugs s

Pharmacogenomic CNS Drug Optimization Platform

Score: 0.524 · neurodegeneration · 2026-04-12

## **Molecular Mechanism and Rationale** The pharmacogenomic CNS drug optimization platform leverages fundamental diffe

CCR2+ Monocyte Depletion as Restoration of CNS Immune Privilege

Score: 0.501 · immunomics · 2026-04-25

CCR2+ Monocyte Depletion as Restoration of CNS Immune Privilege

CNS-Peripheral Cytokine Compartmentalization

Score: 0.455 · clinical-neurology · 2026-04-27

The blood-brain barrier creates distinct cytokine microenvironments where peripheral TNF-α/IL-6 inhibition fails to reac

C1q-Alectinib Complexation Enhances CNS Penetration via Microglial C1qR-Mediated

Score: 0.415 · molecular-biology · 2026-04-21

## Mechanistic Overview C1q-Alectinib Complexation Enhances CNS Penetration via Microglial C1qR-Mediated Uptake and Redi

CCL2 Gradient Disruption via Astrocytic CXCL12 Upregulation for CNS Immune Privi

Score: 0.380 · immunomics · 2026-04-27

This hypothesis proposes that selective upregulation of CXCL12 in astrocytes can restore CNS immune privilege by disrupt

CCR2+ Monocyte Reprogramming via IL-10 Enhancement for CNS Immune Privilege Rest

Score: 0.380 · immunomics · 2026-04-26

Rather than depleting CCR2+ monocytes, this hypothesis proposes reprogramming their phenotype through targeted IL-10 pat

CRP-Mediated CCR2+ Monocyte Recruitment Drives Microglial IL-1β Amplification an

Score: 0.380 · immunomics · 2026-04-27

This hypothesis proposes that circulating hs-CRP directly recruits CCR2+ monocytes to the CNS through upregulation of CC

LDLR-Mediated Reverse Cholesterol Transport Modulation for CNS Drug Delivery

Score: 0.380 · neuropharmacology · 2026-04-27

The LDLR-Mediated Reverse Cholesterol Transport Modulation strategy proposes that CNS drug delivery can be enhanced by h

hs-CRP-Driven CCR2+ Monocyte Recruitment Disrupts CNS Immune Privilege via IL-1β

Score: 0.357 · immunomics · 2026-04-26

Circulating hs-CRP directly triggers CCR2+ monocyte recruitment to the CNS by enhancing CCL2 expression in brain endothe

CNS

Understanding Entity Pages

Wiki Pages (21)

Gut-First vs Brain-First Alpha-Synuclein Propagation in Parkinson's Disease

Validated Hypothesis: pH-Sensitive Bispecific Antibody Targeting Transferrin Receptor for CNS Delivery

Microglia-Targeted Nanoparticles for CNS Delivery

BBB-Transcytosis Shuttle for Episodic CNS PROTAC Delivery

CNS Drug Delivery Methods

Engineered Exosomes for Intranasal CNS Delivery

KCNS3 (Kv9.3)

BBB Transcytosis Shuttle for Episodic CNS PROTAC Delivery

CNS Vasculitis

CNS Lymphatic and Meningeal Immunity in 4R-Tauopathies

RMT-TfR1 Bispecific Antibody Shuttle for CNS Delivery

Exosome-Based CNS Delivery for Gene Therapy

Akkermansia muciniphila in CNS Disorders

Lipid Nanoparticle Delivery for CNS Gene Therapy

AAV Capsid Engineering for CNS-Targeted Neurodegeneration Therapy

Oligodendrocytes in CNS Myelination

KCNS2 Gene

CNS-Selective NLRP3 Inflammasome Inhibitor

Lipid Nanoparticle (LNP) CNS Delivery

AAV Serotype CNS Delivery Optimization Therapy

KCNS1 Gene

Outgoing (0)

Incoming (15)

Targeting Hypotheses (17)

Mentioning Analyses (8)

Systemic immune profiling in neurodegeneration: peripheral inflammation as drive

How do synthetic EVs achieve brain-specific targeting while avoiding reticuloend

What determines blood-brain barrier penetration kinetics for specialized pro-res

What is the therapeutic window between GCS inhibition efficacy and systemic toxi

Do tau-specific HSP90 conformational states exist that differ from other client

What are the specific molecular mechanisms by which AQP4 dysfunction contributes

Systemic immune profiling and peripheral immune contributions to neurodegenerati

Senescent cell clearance as neurodegeneration therapy

Experiments (2)

Related Papers (5)

Debates (17)

Extended debate: Metabolic Reprogramming to Reverse Senescence

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

Hypothesis debate: SASP Modulation Rather Than Cell Elimination

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

Should metabolic reprogramming via SIRT1/NAD+/PGC-1alpha axis be prioritized to

The abstract states that AQP4 'is part of the pathogenesis' of CNS disorders and

The debate hinged on whether HSP90 adopts unique conformations when bound to tau

The debate identified systemic toxicity as a major concern for glucosylceramide

How does chronic peripheral inflammation interact with CNS neuroimmune pathways

Related Research

Glial-Autophagy-Senescence Coupling Defines CNS Therapeutic Windows

Brain-Ester Prodrug Strategy for CNS-Selective HDAC6 Inhibition

MFSD2A-Targeted Lysophosphatidylcholine-SPM Conjugates as CNS-Penetrant Pro-Reso

Pharmacogenomic CNS Drug Optimization Platform

CCR2+ Monocyte Depletion as Restoration of CNS Immune Privilege

CNS-Peripheral Cytokine Compartmentalization

C1q-Alectinib Complexation Enhances CNS Penetration via Microglial C1qR-Mediated

CCL2 Gradient Disruption via Astrocytic CXCL12 Upregulation for CNS Immune Privi

CCR2+ Monocyte Reprogramming via IL-10 Enhancement for CNS Immune Privilege Rest

CRP-Mediated CCR2+ Monocyte Recruitment Drives Microglial IL-1β Amplification an

LDLR-Mediated Reverse Cholesterol Transport Modulation for CNS Drug Delivery

hs-CRP-Driven CCR2+ Monocyte Recruitment Disrupts CNS Immune Privilege via IL-1β